Simulations Plus’ (SLP) “Outperform” Rating Reaffirmed at William Blair

Simulations Plus (NASDAQ:SLP)‘s stock had its “outperform” rating reissued by analysts at William Blair in a report issued on Wednesday,RTT News reports.

SLP has been the subject of several other reports. BTIG Research reduced their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Stephens started coverage on Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective on the stock. Finally, StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Simulations Plus Price Performance

SLP traded down $5.07 during midday trading on Wednesday, reaching $25.32. 394,285 shares of the company’s stock traded hands, compared to its average volume of 320,626. Simulations Plus has a 52 week low of $24.00 and a 52 week high of $51.22. The firm has a fifty day moving average of $29.78 and a two-hundred day moving average of $34.16. The stock has a market capitalization of $508.55 million, a price-to-earnings ratio of 51.67 and a beta of 0.80.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The company had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same period last year, the business earned $0.18 EPS. Simulations Plus’s quarterly revenue was up 19.9% compared to the same quarter last year. Sell-side analysts forecast that Simulations Plus will post 1.1 EPS for the current year.

Insiders Place Their Bets

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $27.66, for a total transaction of $553,200.00. Following the transaction, the director now directly owns 3,462,584 shares of the company’s stock, valued at $95,775,073.44. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 19.40% of the company’s stock.

Institutional Trading of Simulations Plus

Several hedge funds have recently modified their holdings of SLP. Barclays PLC increased its position in Simulations Plus by 390.6% during the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after buying an additional 22,669 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after acquiring an additional 18,924 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Simulations Plus in the 2nd quarter worth approximately $811,000. State Street Corp increased its stake in Simulations Plus by 4.7% during the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after purchasing an additional 28,953 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock worth $1,279,000 after buying an additional 32,002 shares during the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.